ZENTALIS PHARMACEUTICALS INC's ticker is ZNTL and the CUSIP is 98943L107. A total of 132 filers reported holding ZENTALIS PHARMACEUTICALS INC in Q1 2022. The put-call ratio across all filers is 0.27 and the average weighting 0.2%.
Quarter-by-quarter ownership
Value | Shares | Weighting | ||||
---|---|---|---|---|---|---|
Q3 2023 | $2,739,414 | -25.5% | 136,561 | +4.8% | 0.00% | 0.0% |
Q2 2023 | $3,675,198 | +733.6% | 130,280 | +408.3% | 0.00% | – |
Q1 2023 | $440,888 | -12.6% | 25,633 | +2.3% | 0.00% | – |
Q4 2022 | $504,668 | -13.9% | 25,058 | -7.2% | 0.00% | – |
Q3 2022 | $586,000 | -11.7% | 27,016 | +14.4% | 0.00% | – |
Q2 2022 | $664,000 | -85.2% | 23,625 | -75.8% | 0.00% | -100.0% |
Q1 2022 | $4,497,000 | -75.6% | 97,455 | -55.5% | 0.00% | -75.0% |
Q4 2021 | $18,419,000 | +111.3% | 219,115 | +67.5% | 0.00% | +100.0% |
Q3 2021 | $8,718,000 | +12.8% | 130,812 | -9.9% | 0.00% | 0.0% |
Q2 2021 | $7,728,000 | -23.6% | 145,249 | -37.7% | 0.00% | -33.3% |
Q1 2021 | $10,110,000 | -29.5% | 233,007 | -15.6% | 0.00% | -25.0% |
Q4 2020 | $14,339,000 | +60.6% | 276,069 | +1.1% | 0.00% | +33.3% |
Q3 2020 | $8,928,000 | -33.0% | 273,109 | -1.5% | 0.00% | -40.0% |
Q2 2020 | $13,320,000 | – | 277,393 | – | 0.01% | – |
Download |
Other shareholders
Name | Shares | Value | Weighting ↓ |
---|---|---|---|
Decheng Capital Management III (Cayman), LLC | 1,824,583 | $39,520,000 | 14.33% |
TYBOURNE CAPITAL MANAGEMENT (HK) LTD | 2,301,771 | $49,857,000 | 4.79% |
Matrix Capital Management Company, LP | 9,199,973 | $199,271,000 | 3.81% |
Integral Health Asset Management, LLC | 550,000 | $11,913,000 | 2.31% |
Avidity Partners Management LP | 4,223,100 | $91,472,000 | 1.86% |
Affinity Asset Advisors, LLC | 170,000 | $3,682,000 | 1.03% |
Eventide Asset Management | 1,861,000 | $40,309,000 | 0.79% |
Sofinnova Investments, Inc. | 583,357 | $12,636,000 | 0.74% |
Nicholas Investment Partners, LP | 158,704 | $3,438,000 | 0.32% |
SECTORAL ASSET MANAGEMENT INC | 60,000 | $1,300,000 | 0.26% |